Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | Chief Financial Officer | February 22, 2024 | February 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date February 22, 2024 · Filed February 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2034-02-21 | Direct | 213,886 |
Reported balance
After 2024-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-22 · Grant · Acquired 213,886 · Balance 213,886 F1: One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 24, 2024 02:00 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 213,886 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001628280-24-006725 · wk-form4_1708740022.xml · derivative · entry 1 Gerber Brianna · CIK 0001942395 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,886 Underlying: Common Stock · 213,886 shares Expires 2034-02-21 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:12 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,000 | $1.41 | $7,050.00 |
DisclosureSEC source: 0001628280-23-040625 · wk-form4_1701724341.xml · nonDerivative · entry 1 Gerber Brianna · CIK 0001942395 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,436 Read SEC document |
| August 12, 2023 Filed Aug 16, 2023 01:11 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionRestricted Stock Unit · Derivative | 22,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029599 · wk-form4_1692148297.xml · derivative · entry 3 Gerber Brianna · CIK 0001942395 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,872 Underlying: Common Stock · 22,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested. F1 · kind: Vesting of restricted stock units ("RSUs") previously granted to the Reporting Person. F4 · derivative.exercise_date: RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023. F4 · derivative.expiration_date: RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023. Read SEC document |
| August 12, 2023 Filed Aug 16, 2023 01:11 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 22,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-029599 · wk-form4_1692148297.xml · nonDerivative · entry 1 Gerber Brianna · CIK 0001942395 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units ("RSUs") previously granted to the Reporting Person. F2 · price: On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:09 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 163,996 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001628280-23-004092 · wf-form4_167667171935135.xml · derivative · entry 1 Gerber Brianna · CIK 0001942395 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,996 Underlying: Common Stock · 163,996 shares Expires 2033-02-14 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on February 15, 2024 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| August 12, 2022 Filed Aug 13, 2022 01:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantRestricted Stock Unit · Derivative | 67,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-022756 · wf-form4_166035275685057.xml · derivative · entry 2 Gerber Brianna · CIK 0001942395 · SVP Finance / Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,308 Underlying: Common Stock · 67,308 shares Expires not disclosed F2 · derivative.exercise_price: On August 12, 2022, the reporting person was awarded Restricted Stock Units ("RSUs") which will be settled in shares of Common Stock when vested. F3 · derivative.exercise_date: RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023. F3 · derivative.expiration_date: RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023. Read SEC document |
| August 12, 2022 Filed Aug 13, 2022 01:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 100,460 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001628280-22-022756 · wf-form4_166035275685057.xml · derivative · entry 1 Gerber Brianna · CIK 0001942395 · SVP Finance / Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,460 Underlying: Common Stock · 100,460 shares Expires 2032-08-11 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on August 12, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.